FDA Adverse Event Other Summary report: N

COULTER ACT 5 DIFF ANALYZER

MDR report key: 1364057 · Received January 16, 2009

Report

Report Number
1061932-2009-00001
Event Type
Other
Date Received
January 16, 2009
Date of Event
December 15, 2008
Report Date
January 16, 2009
Manufacturer
BECKMAN COULTER, INC.
Product Code
GKZ
PMA / PMN Number
K003677
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MN, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

SAMPLES WERE DRAWN IN 4 ML EDTA VACUTAINERS AND ANALYZED THE SAME DAY. QC IS RUN DAILY AND THE INSTRUMENT RECOVERED WITHIN QC SPECIFICATIONS. THE FIELD SERVICE ENGINEER (FSE) CONFIRMED THE PROBLEM BY RUNNING REPRODUCIBILITY. THE FSE REBUILT THE SAMPLE AND REAGENT SYRINGES, CHECKED TRAVERSE BELT TENSION, LUBED RAILS, ADJUSTED CARRIAGE STOP COLLAR, CHECKED PROBE ALIGNMENT, AND VERIFIED CONDITION OF PROBE. AS OF 2009, NO FURTHER LOW/ERRATIC RESULTS HAVE BEEN REPORTED. A CLEAR ROOT CAUSE HAS NOT BEEN DETERMINED TO DATE FOR THIS EVENT. A MALFUNCTION WILL BE ASSUMED FOR THE PURPOSE OF THIS REPORT.

Description of Event or Problem · 1

A CUSTOMER CONTACTED BECKMAN COULTER INC. (BCI) REGARDING ERRONEOUSLY LOW PLATELET (PLT) AND HEMOGLOBIN (HGB) RESULTS PRODUCED BY THE COULTER ACT 5 DIFF ANALYZER. SEVERAL PT SAMPLES WERE TESTED FOR PLT AND GAVE RESULTS IN THE RANGE OF 121 - 320 X 10^3 CELLS/ML. THESE SAMPLES WERE ALSO TESTED FOR HGB AND GAVE RESULTS IN THE RANGE OF 8.7 - 16.8G/DL. SAMPLE ONE WHEN TESTED ON THE COULTER ACT 5 DIFF ANALYZER GAVE A PLT RESULT OF 144 X 10 TO THE THIRD POWER CELLS/ML AND AN HGB RESULT OF 10.2G/DL. IT WAS TESTED IN A REFERENCE LAB UPON WHICH IT GAVE A PLT RESULT OF 189 X 10^3 CELLS/ML AND A HGB RESULT OF 13.2G/DL WHICH WERE CONSIDERED CORRECT. THE ERRONEOUS RESULTS WERE REPORTED OUTSIDE OF THE LABORATORY. IT IS UNK IF THERE WAS AN AFFECT TO PT OR USER WITH REGARDS TO THIS EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 COULTER ACT 5 DIFF ANALYZER AUTOMATED DIFFERENTIAL CELL COUNTER GKZ BECKMAN COULTER, INC. ACT 5 DIFF CP NA

Patients

Seq Age Sex Outcome Treatment
1 NA